The outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV). The CoV spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Here, we identified the receptor-binding domain (RBD) in SARS-CoV-2 S protein and found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibited significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for prevention of SARS-CoV-2 and SARS-CoV infection.
【저자키워드】 SARS-CoV-2, viral infection, Immunotherapy, Spike protein, 2019 novel coronavirus, Receptor-binding domain, viral inhibitor, cross-neutralization, 【초록키워드】 COVID-19, coronavirus disease, antibodies, Coronavirus disease 2019, ACE2, coronavirus, Vaccines, S protein, Therapeutics, Human, 2019-nCoV, Infection, ACE2 receptor, severe acute respiratory syndrome Coronavirus, angiotensin-converting enzyme 2, binding affinity, Novel coronavirus, Protein, 2019 novel coronavirus, Viral, Receptor-binding domain, outbreak, RBD, CoV, target, receptors, respiratory, entry inhibitors, fusion, RBD protein, specific antibodies, binding, SARS-CoV-2 S protein, Entry inhibitor, angiotensin, Safe, SARS-CoV-2 RBD, host cells, causative agent, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, global public health, enzyme, CoV infection, SARS-CoV infection, SARS-CoV-2 and SARS-CoV infection, ACE2-expressing cells, SARS-CoV RBD, SARS-CoV RBD-based vaccines, SARS-CoV RBD-induced antisera, SARS-CoV RBD-specific antibodies, SARS-CoV-2 RBD protein, effective, develop, exhibited, in viral, the receptor-binding domain, significantly higher, inhibiting, cross-react, cross-neutralize SARS-CoV-2, SARS-CoV RBD-based vaccine, SARS-CoV RBD-specific antibody, the RBD protein, 【제목키워드】 Vaccine, Viral, RBD, characterization, the receptor-binding domain, viral attachment inhibitor,